Event details
Date: Friday, February 20, 2026
Time: 8:00 AM – 6:00 PM
Location: Leslie Dan Faculty of Pharmacy, 144 College St., Toronto, ON. Canada M5S 3M2
Are you passionate about the future of AI, gene editing, drug screening, and diagnostics? Don’t miss out on the chance to connect with leading experts from academia, industry, and government at PRiME’s 7th Annual Symposium!
This event brings together basic science researchers, clinician scientists, industry pioneers, investors, and policymakers to delve into the latest advancements in precision medicine. Explore groundbreaking research, participate in engaging conversations, and discover how today’s innovations are paving the way for tomorrow’s treatments.
Event highlights:
- Networking opportunities with professionals across academia, industry, venture capital, and partnering organizations
- Keynote speakers from BIIE/ETH Zürich and Bayer
- Captivating panel discussion from industry leaders
- Poster presentations showcasing emerging talents from U of T and affiliated hospitals
- Lightning talks from the 2025 PRiME Fellows
Registration details
| Attendee categories | Pricing |
| Student / Postdocs / Trainees | $25 |
| PI / Faculty / Staff | $50 |
| Government / Not-for-profit | $75 |
| Industry / Startup representatives | $100 |
Cancellation policy
- Cancellations will be accepted until January 31, 2026 and are subject to a processing fee. Refunds will not be processed after this date.
- Requests for cancellation must be made in writing to prime.initiative@utoronto.ca.
- Registrations are non-transferable.
Poster abstract submission
Submit your abstract for the 7th Annual Symposium on the themes of AI, gene editing, drug screening, and diagnostics. Trainees and PIs from PRiME-member labs are encouraged to submit a 350-word abstract.
Agenda
Coming soon
Keynote speakers
Scientific Keynote — Berend Snijder, The Botnar Institute of Immune Engineering (BIIE)
Group Leader, Botnar Institute of Immune Engineering and ETH Zurich
Dr. Berend Snijder is a group leader at the Botnar Institute of Immune Engineering and ETH Zurich, as well as at the Comprehensive Cancer Center Zurich and the Swiss Institute of Bioinformatics. Research in the Snijder Lab focuses on the systematic functional and multi-omic profiling of human tissues in health and disease, with a strong bioinformatics and clinical/translational focus. He is a leading figure in the field of functional precision medicine, having developed the pharmacoscopy platform that has led to two successful precision oncology trials (EXALT-1 and DARTT-1), which they currently evaluate in multiple randomized & controlled interventional clinical trials for the treatment of aggressive cancers. Berend has co-founded three spin-off companies: Allcyte (acquired by Exscientia, now Recursion); Prevision Medicine, working to implement pharmacoscopy as a scalable functional diagnostic device for oncology; and Graph Therapeutics, developing AI- and functionally driven precision immunology.oming soon
Industry Keynote — Alberto Nobili, Bayer
Vice President & Head, Bayer Co.Lab Cambridge
Alberto Nobili serves as the Vice President, Head of Bayer Co.Lab Cambridge at Bayer Pharmaceuticals, a position he has held since his promotion in August 2025. In this role, Alberto is instrumental in identifying and cultivating relationships with new tenants, providing strategic guidance, and facilitating connections to support their growth both within Bayer and across the broader Boston innovation ecosystem. Also, Alberto spearheaded the launch of the Bayer Co.Lab Connect program in February 2025, enabling the expansion of Bayer Co.Lab beyond its initial four locations.
Before joining Bayer, Alberto co-founded and worked for Dynamic Cell Therapies Inc., a Dana-Farber Cancer Institute spinoff company focused on targeting liquid and solid tumors using Next-Generation CAR-T cells. The company, co-founded alongside renowned figures such as Ken C. Anderson and Marc Cohen, is rooted in research conducted during Alberto’s postdoctoral training at the Dana-Farber Cancer Institute / Harvard Medical School. In his pivotal role at Dynamic Cell Therapies, Alberto engaged with investors, key opinion leaders (KOLs), and legal experts, playing a crucial part in securing funding, protecting intellectual property, facilitating technology transfer, and shaping the company’s strategic direction.
In addition, Alberto co-founded 42N Advisors Benefit Corp. in 2021, where he served as Vice President and Board Member. The company is dedicated to supporting high-tech enterprises with Italian leadership in establishing a presence within the Boston innovation ecosystem.
Alberto completed his postdoctoral training at Dana-Farber Cancer Institute and earned his PhD from the University of Greifswald, Germany, specializing in biotechnology with a focus on protein engineering through directed evolution. Over the course of his career, Alberto has authored 12 publications and is listed as an inventor on 8 patent filings, underscoring his contributions to scientific innovation and entrepreneurship.